CAMBRIDGE, MA, USA I September 30, 2022 I Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody. RoACTEMRA® is indicated in Europe as an intravenous formulation for severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate, moderate to severe rheumatoid arthritis in adults who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists, as well as for the treatment of patients from 2 years of age with juvenile idiopathic polyarthritis who have responded inadequately to previous therapy with methotrexate, patients from 2 years of age with active systemic juvenile idiopathic arthritis who have responded inadequately to prior therapy with NSAIDs and systemic corticosteroids. RoACTEMRA® is also used to treat chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in adults or paediatric patients 2 years of age or older, and severe coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. The MAA includes positive Phase 32 data for BIIB800 from the clinical program of a multicenter, multinational, randomized, double-blind, parallel-group, active-control study, designed to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of BIIB800 compared to RoACTEMRA® in 621 patients with moderate to severe rheumatoid arthritis with inadequate response to methotrexate. The Phase 3 data from the comparative clinical trial demonstrated that the biosimilar candidate BIIB800 has equivalent efficacy and a comparable PK, safety and immunogenicity profile to reference tocilizumab and these positive results were presented at the European Congress of Rheumatology on June 3, 2022.
“The EMA filing acceptance for BIIB800 brings us a step closer to potentially offering broader patient access to another more affordable and important new biosimilar treatment option in Europe, and we look forward to continued engagement with the EMA throughout the review process,” said Ian Henshaw, Head of Global Biosimilars at Biogen. “If approved, BIIB800 will be a valuable treatment option for people with chronic immune mediated inflammatory diseases. We believe our biosimilar offerings are essential as we collaborate with payers and health authorities with the goal of generating savings to ensure sustainable healthcare systems.”
On April 8th, 2021, Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement to develop, manufacture and commercialize BIIB800. Biogen has exclusive regulatory, manufacturing and commercial rights to BIIB800 in all countries excluding China (including Hong Kong, Macau and Taiwan).
Biosimilars are products that have been demonstrated to be similar in efficacy and safety to the originator’s reference product, with the advantage that they offer cost savings and promote sustainable access to therapies. Biogen is committed to advancing development, manufacturing and commercialization of additional biosimilar candidates with the goal of optimizing the disease management with biosimilars and helping more people and healthcare systems across the world to benefit from biologics treatments.
About Biogen
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and developed the first and only approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing one of the industry’s most diversified pipelines in neuroscience that will transform the standard of care for patients in several areas of high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil fuels across the company’s operations, build collaborations with renowned institutions to advance the science to improve human health outcomes, and support underserved communities.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
References:
- ACTEMRA®/RoACTEMRA® is a registered trademark of Genentech, Inc.
- https://ard.bmj.com/content/annrheumdis/81/Suppl_1/388.2.full.pdf
SOURCE: Biogen
Post Views: 292
CAMBRIDGE, MA, USA I September 30, 2022 I Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody. RoACTEMRA® is indicated in Europe as an intravenous formulation for severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate, moderate to severe rheumatoid arthritis in adults who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists, as well as for the treatment of patients from 2 years of age with juvenile idiopathic polyarthritis who have responded inadequately to previous therapy with methotrexate, patients from 2 years of age with active systemic juvenile idiopathic arthritis who have responded inadequately to prior therapy with NSAIDs and systemic corticosteroids. RoACTEMRA® is also used to treat chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in adults or paediatric patients 2 years of age or older, and severe coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. The MAA includes positive Phase 32 data for BIIB800 from the clinical program of a multicenter, multinational, randomized, double-blind, parallel-group, active-control study, designed to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of BIIB800 compared to RoACTEMRA® in 621 patients with moderate to severe rheumatoid arthritis with inadequate response to methotrexate. The Phase 3 data from the comparative clinical trial demonstrated that the biosimilar candidate BIIB800 has equivalent efficacy and a comparable PK, safety and immunogenicity profile to reference tocilizumab and these positive results were presented at the European Congress of Rheumatology on June 3, 2022.
“The EMA filing acceptance for BIIB800 brings us a step closer to potentially offering broader patient access to another more affordable and important new biosimilar treatment option in Europe, and we look forward to continued engagement with the EMA throughout the review process,” said Ian Henshaw, Head of Global Biosimilars at Biogen. “If approved, BIIB800 will be a valuable treatment option for people with chronic immune mediated inflammatory diseases. We believe our biosimilar offerings are essential as we collaborate with payers and health authorities with the goal of generating savings to ensure sustainable healthcare systems.”
On April 8th, 2021, Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement to develop, manufacture and commercialize BIIB800. Biogen has exclusive regulatory, manufacturing and commercial rights to BIIB800 in all countries excluding China (including Hong Kong, Macau and Taiwan).
Biosimilars are products that have been demonstrated to be similar in efficacy and safety to the originator’s reference product, with the advantage that they offer cost savings and promote sustainable access to therapies. Biogen is committed to advancing development, manufacturing and commercialization of additional biosimilar candidates with the goal of optimizing the disease management with biosimilars and helping more people and healthcare systems across the world to benefit from biologics treatments.
About Biogen
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and developed the first and only approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing one of the industry’s most diversified pipelines in neuroscience that will transform the standard of care for patients in several areas of high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil fuels across the company’s operations, build collaborations with renowned institutions to advance the science to improve human health outcomes, and support underserved communities.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
References:
- ACTEMRA®/RoACTEMRA® is a registered trademark of Genentech, Inc.
- https://ard.bmj.com/content/annrheumdis/81/Suppl_1/388.2.full.pdf
SOURCE: Biogen
Post Views: 292